Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (pericytes) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 478 | 0.82 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15627
Sealed predictions
- CCL26 in dopamine neurons, braak+0.07 (p 0.849) → -0.40 (p 0.281)receipt 15635
Swarm cases
receipt 15635: CCL26 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.722, n 18), 95% CI -0.53 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.515, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.19 (p 0.455, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.02, sign flips 3; without severely affected donors -0.09 (p 0.722, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCL26 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts